8 unknown, 4 recruiting, 3 completed, 3 terminated. 7 Phase 2, 5 Not applicable, 3 Phase 3, 2 Phase 4, 1 Early Phase 1.
Follow DEB-TACE: new trials by email Literature Review of DEB-TACE trials Research Report on DEB-TACE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma DEB-TACE, Toripalimab, Lenvatinib - Liver Cancer | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 29 | 2026-06-30 | 2026-07-06 |
| DEB-TACE vs cTACE in HCC After TIPS DEB-TACE, cTACE - Hepatocellular Carcinoma (HCC), TACE | Phase 3 | Recruiting | First Affiliated Hospital, Sun Yat-Sen University | 206 | 2025-12-01 | 2026-05-01 |
| ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC Lenvatinib, Pembrolizumab, Atezolizumab - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Peking Union Medical College Hospital | 300 | 2025-02-19 | 2025-12-01 |
| DEB-TACE Prior to Liver Transplantation in the Treatment of HCC DEB-TACE - Liver Cancer | Phase 4 | Recruiting | RenJi Hospital | 40 | 2024-10-16 | 2024-10-18 |
| DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC DEB-TACE+HAIC, DEB-TACE - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 130 | 2024-05-01 | 2025-02-20 |
| Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma DEB-TACE, Lenvatinib plus pucotenlimab - Cholangiocarcinoma Non-resectable | Phase 2 | Unknown | Tongji Hospital | 36 | 2023-12-09 | 2024-01-09 |
| DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial DEB-TACE and HAIC, DEB-TACE - HCC | Not applicable | Unknown | Xuhua Duan | 220 | 2023-03-07 | 2023-03-29 |
| DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma drug eluting beads-transcatheter arterial chemoembolization, envatinib plus anti-PD(L)1 - Cholangiocarcinoma Non-resectable | Unknown | Ze-yang Ding, MD | 100 | 2022-02-01 | 2024-01-09 | |
| PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer DEB-TACE, PVL/PVE+DEB-TACE - Hepatocellular Carcinoma | Not applicable | Unknown | Tongji Hospital | 200 | 2021-12-01 | 2023-12-19 |
| Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC Tremelimumab, Durvalumab, Y-90 SIRT - Hepatocellular Carcinoma Non-resectable, HCC | Phase 2 | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 55 | 2020-12-15 | 2026-06-23 |
| Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC) DEB-TACE, cTACE - Hepatocellular Carcinoma | Not applicable | Unknown | Air Force Military Medical University, China | 344 | 2020-09-15 | 2020-02-05 |
| Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria; DEB-TACE, cTACE, Drug-eluting Beads - Hepatocellular Carcinoma | Not applicable | Unknown | Beijing Tsinghua Chang Gung Hospital | 226 | 2020-03-18 | 2021-02-04 |
| Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma DEB-TACE, TAE - Carcinoma, Hepatocellular | Phase 3 | Unknown | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 154 | 2019-12-04 | 2021-03-19 |
| Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC Sintilimab, DEB-TACE - Hepatocellular Carcinoma | Phase 2 | Unknown | Zhejiang University | 61 | 2019-11-20 | 2022-06-09 |
| A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer Drug Eluting Bead Transarterial Chemoembolization, Nivolumab - Liver Cancer | Early Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 20 | 2017-04-28 | 2026-08-04 |
| Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR) Trans-arterial Chemo-Embolization, Doxorubicin, Stereotactic Ablative Radiotherapy - Liver Neoplasms, Hepatocellular Cancer | Phase 2 | Terminated | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 3 | 2017-02-20 | 2017-11-07 |
| A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma DEB-TACE, Sorafenib - Hepatocellular Carcinoma, Hepatoma | Phase 3 | Terminated | Boston Scientific Corporation | 2 | 2015-11-01 | 2021-02-12 |
| DEB-TACE for Hepatocellular Carcinoma DEB-TACE - Hepatocellular Carcinoma | Not applicable | Terminated | Surefire Medical, Inc. | 170 | 2015-08-01 | 2018-06-21 |
| Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients Trans-arterial chemoembolization (TACE), TACE with Drug Eluting Beads procedure - HepatoCellular Carcinoma | Phase 4 | Completed | Ain Shams University | 50 | 2015-07-01 | 2020-10-22 |
| Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC DEB-TACE - Hepatocellular Carcinoma | Completed | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 131 | 2015-03-01 | 2021-03-30 |
Carcinoma, Hepatocellular (13) · Liver Neoplasms (4) · Cholangiocarcinoma (2)
Tongji Hospital (2) · Ain Shams University (1) · Air Force Military Medical University, China (1) · Beijing Tsinghua Chang Gung Hospital (1) · Boston Scientific Corporation (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1) · Memorial Sloan Kettering Cancer Center (1) · Peking Union Medical College Hospital (1) · RenJi Hospital (1) · Second Affiliated Hospital of Guangzhou Medical University (1) · Shanghai Zhongshan Hospital (1)
China (11) · United States (3) · Belgium (1) · Germany (1) · Italy (1) · Spain (1)
Ze-yang Ding, M.D. (2) · Anastasia Becker (1) · Arndt Vogel, Prof. Dr. (1) · James Harding, MD (1) · Jianjun Zhang, MD (1) · Jose Urbano, MD, PhD,EBIR (1) · Rita Golfieri, Professor (1) · Salah-Eddin Al-Batran, Prof. Dr. (1) · Wan-guang Zhang (1) · Xuhua Xuhua, Ph.D. (1)
2019 (1)